Calidi Biotherapeutics to Present RedTail Platform at H.C. Wainwright Global Investment Conference
Calidi Biotherapeutics will showcase its innovative RedTail platform at the H.C. Wainwright conference, highlighting its potential to revolutionize cancer treatment through systemic delivery of genetic medicines to metastatic sites.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, in New York. The presentation, available on-demand starting September 5 at 7 a.m. ET, will focus on the company's proprietary RedTail platform, which represents a significant advancement in immuno-oncology therapeutics.
The RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic cancer sites. This technology is engineered to protect the virus from immune clearance, enabling effective delivery to tumor locations where it can induce tumor lysis and deliver potent genetic medicines. The platform's ability to reach distal disease sites through systemic administration addresses a critical challenge in cancer treatment, particularly for metastatic cancers that have traditionally been difficult to target effectively.
Calidi's lead candidate from the RedTail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs. The company is also developing protected virotherapies for intratumoral and localized administration, focusing on injectable cancer indications. More information about Calidi's developments can be found at https://ibn.fm/CLDI.
The presentation at the prestigious H.C. Wainwright conference provides Calidi with a platform to showcase its innovative approach to institutional investors and industry stakeholders. The timing of this presentation is particularly significant as the company progresses with its IND-enabling studies, potentially positioning itself for future clinical trials and regulatory milestones. The availability of an on-demand presentation starting September 5 allows for broader accessibility to investors and interested parties who cannot attend the live event.
This development matters because it represents a potential paradigm shift in cancer treatment methodology. Traditional cancer therapies often struggle to effectively reach metastatic sites, limiting their efficacy against advanced-stage cancers. Calidi's RedTail platform addresses this fundamental challenge by enabling systemic delivery of therapeutic agents directly to metastatic locations. The technology's dual mechanism of inducing tumor lysis while delivering genetic medicines could potentially enhance treatment outcomes for patients with metastatic cancers who currently have limited therapeutic options.
The implications of this announcement extend beyond immediate investor interest. Success with the RedTail platform could establish new standards for targeted cancer therapy delivery and open possibilities for treating various metastatic cancers that currently have poor prognosis. As the company moves forward with its clinical development program, the medical community will be watching closely to see if this innovative approach can translate laboratory success into meaningful patient benefits.